Patents by Inventor Marie-Eve Hamelin

Marie-Eve Hamelin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Attenuated virus strain and use thereof as a vaccine
    Patent number: 11504424
    Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: November 22, 2022
    Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE LAVAL
    Inventors: Manuel Rosa-Calatrava, Guy Boivin, Julia Dubois, Mario Andres Pizzorno, Olivier Terrier, Marie-Eve Hamelin, Marie-Helene Cavanagh
  • NEW ATTENUATED VIRUS STRAIN AND USE THEREOF AS A VACCINE
    Publication number: 20210283239
    Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.
    Type: Application
    Filed: July 12, 2019
    Publication date: September 16, 2021
    Inventors: Manuel ROSA-CALATRAVA, Guy BOIVIN, Julia DUBOIS, Mario Andres PIZZORNO, Olivier TERRIER, Marie-Eve HAMELIN, Marie-Helene CAVANAGH
  • Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections
    Publication number: 20140378502
    Abstract: The present invention is concerned with the use of Protease-Activated Receptor-1 (PAR1) inhibitors for preventing or treating a Paramyxoviridae infection in a subject. Described herein are methods, compounds and pharmaceutical compositions useful in addressing such infections, and more particularly infections from human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV).
    Type: Application
    Filed: May 11, 2012
    Publication date: December 25, 2014
    Applicants: Université Laval, Institut National de la Recherche Agronomique
    Inventors: Béatrice Riteau, Guy Boivin, Laetitia Aerts, Marie-Eve Hamelin